Weight gain secondary to the use of Janus kinase inhibitors
- 23.08.2023
- REVIEW
- Verfasst von
- Peter Yi Ch’en
- Justin Ng
- Eingun James Song
- Erschienen in
- Archives of Dermatological Research | Ausgabe 10/2023
Auszug
Currently, abrocitinib, baricitinib, ruxolitinib, and upadacitinib are Food and Drug Administration (FDA)-approved JAK inhibitors (JAKi) for dermatologic indications [1]. Common safety concerns include malignancy, major adverse cardiac events, thrombosis, and serious infections. In the author’s experience, several patients have noted significant weight gain (WG) since starting a JAKi. Therefore, we conducted a review using PubMed and Embase databases, prescribing information, and direct pharmaceutical company (Pfizer & Eli Lilly) inquiry to assess incidence of WG across their indications. …
Anzeige
- Titel
- Weight gain secondary to the use of Janus kinase inhibitors
- Verfasst von
-
Peter Yi Ch’en
Justin Ng
Eingun James Song
- Publikationsdatum
- 23.08.2023
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Archives of Dermatological Research / Ausgabe 10/2023
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X - DOI
- https://doi.org/10.1007/s00403-023-02710-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.